Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Comprehensive Clinical Guide

1. Comprehensive Introduction & Overview

Eosinophilic Granulomatosis with Polyangiitis (EGPA), historically known as Churg-Strauss Syndrome, is a rare, systemic, small-to-medium vessel necrotizing vasculitis characterized by severe asthma, peripheral blood eosinophilia, and extravascular granulomatous inflammation.

Classified under the ANCA-associated vasculitides (AAV), EGPA represents a complex immunological challenge. Unlike other forms of AAV (such as Granulomatosis with Polyangiitis or Microscopic Polyangiitis), EGPA is uniquely distinguished by its strong association with atopic disease, particularly late-onset asthma and eosinophil-mediated tissue damage. The disease typically follows a triphasic clinical course, progressing from an allergic prodrome to eosinophilic infiltration and eventually to overt vasculitis.

2. Deep-Dive: Etiology and Pathophysiology

The Mechanisms of Injury

The pathogenesis of EGPA is multifactorial, involving a dysregulated immune response where both T-helper 2 (Th2) lymphocytes and eosinophils play central roles.

• The Th2 Drive: There is an upregulation of cytokines such as IL-4, IL-5, and IL-13. IL-5 is particularly critical, as it promotes the maturation, activation, and survival of eosinophils.
• Eosinophil-Mediated Damage: Eosinophils infiltrate tissues and release toxic granular proteins, including Major Basic Protein (MBP), Eosinophil Peroxidase (EPO), and Eosinophil Cationic Protein (ECP), leading to direct epithelial and endothelial cell necrosis.
• ANCA Production: Approximately 40-60% of patients are ANCA-positive, typically targeting myeloperoxidase (MPO). However, the absence of ANCA does not rule out the diagnosis, as the disease mechanism in seronegative patients is likely driven more heavily by eosinophilic inflammation than by classic immune-complex vasculitis.

The Triphasic Clinical Progression

1. Prodromal Phase: Often lasts for years; characterized by late-onset asthma, allergic rhinitis, and nasal polyposis.
2. Eosinophilic Phase: Peripheral blood eosinophilia (>10% or >1,500 cells/µL) with eosinophilic infiltration of organs, most commonly the lungs, heart, and gastrointestinal tract.
3. Vasculitic Phase: The life-threatening stage characterized by small-to-medium vessel vasculitis, leading to purpura, mononeuritis multiplex, and glomerulonephritis.

3. Clinical Indications & Diagnostic Criteria

Diagnosis relies on the 1990 American College of Rheumatology (ACR) criteria and the 2012 Chapel Hill Consensus Conference definitions.

ACR Diagnostic Criteria (4 of 6 required)

Clinical Presentation by System

• Respiratory: Severe, difficult-to-control asthma is the hallmark. Patients often require systemic corticosteroids to maintain stability.
• Neurological: Mononeuritis multiplex is common, presenting as sudden onset of asymmetric sensory or motor deficits.
• Cardiac: The leading cause of mortality. Manifests as eosinophilic myocarditis, endomyocardial fibrosis, or pericarditis.
• Dermatological: Palpable purpura, subcutaneous nodules, or livedo reticularis.
• Gastrointestinal: Abdominal pain, eosinophilic gastroenteritis, or bowel perforation due to vasculitis.

4. Risks, Side Effects, and Contraindications

Management Risks

Treatment generally involves high-dose corticosteroids followed by immunosuppressive agents (e.g., Cyclophosphamide, Rituximab, or Mepolizumab).

• Corticosteroids: Long-term use risks osteoporosis, diabetes, cataracts, and iatrogenic Cushing’s syndrome.
• Cyclophosphamide: High risk of hemorrhagic cystitis, bladder cancer, infertility, and myelosuppression.
• Mepolizumab (Anti-IL-5): Generally well-tolerated, but carries risks of hypersensitivity reactions and increased susceptibility to parasitic infections (due to eosinophil inhibition).

Contraindications

• Live Vaccines: Contraindicated in patients on high-dose immunosuppression.
• Non-Selective Beta-Blockers: Should be used with extreme caution in patients with severe, brittle asthma.

5. Differential Diagnosis

It is critical to distinguish EGPA from other eosinophilic disorders:
1. Hypereosinophilic Syndrome (HES): Lacks the hallmark features of asthma and vasculitis.
2. Granulomatosis with Polyangiitis (GPA): Generally lacks asthma and significant peripheral eosinophilia.
3. Eosinophilic Pneumonia: Usually limited to the lungs; lacks systemic vasculitic features.
4. Drug-Induced Eosinophilia: Must rule out recent exposure to medications like antibiotics or anticonvulsants.

6. Key Diagnostic Tests

• Complete Blood Count (CBC): To identify absolute eosinophil count (AEC).
• ANCA Testing: MPO-ANCA is the most common finding.
• Biopsy (Gold Standard): Biopsy of affected tissue (skin, sural nerve, or lung) showing necrotizing vasculitis and eosinophilic infiltrates.
• Cardiac MRI: Essential for detecting subclinical eosinophilic myocarditis.
• Pulmonary Function Tests (PFTs): To quantify asthma severity and airflow obstruction.

7. Prognosis and Long-Term Management

The prognosis for EGPA has improved significantly with modern immunosuppressive protocols. The Five-Factor Score (FFS) is used to predict mortality:
* Age > 65
* Cardiac insufficiency
* Renal insufficiency (Creatinine > 1.58 mg/dL)
* Gastrointestinal involvement
* Central nervous system involvement

Patients with an FFS of 0 generally have a favorable prognosis, while those with an FFS ≥ 1 require aggressive induction therapy. Long-term management requires a multidisciplinary team (Rheumatology, Pulmonology, Cardiology, and Neurology).

8. Frequently Asked Questions (FAQ)

1. Is EGPA the same as asthma?
No. While asthma is a primary feature, EGPA is a systemic vasculitis. Most people with asthma do not have EGPA.

2. What is the role of Mepolizumab in EGPA?
Mepolizumab is an anti-IL-5 monoclonal antibody. It is FDA-approved for the treatment of relapsing or refractory EGPA, as it directly targets the eosinophil-driving cytokine.

3. Is EGPA hereditary?
There is no evidence that EGPA is directly inherited. It is considered an autoimmune condition with likely environmental triggers.

4. Can EGPA be cured?
Currently, there is no "cure." However, it is a manageable chronic condition, and many patients achieve long-term clinical remission.

5. What is the most dangerous complication?
Cardiac involvement, specifically eosinophilic myocarditis, is the leading cause of death in EGPA patients.

6. Why is a biopsy necessary?
A biopsy provides histological confirmation of vasculitis and extravascular eosinophils, which is the gold standard for a definitive diagnosis.

7. Does the ANCA status change the treatment?
Yes. ANCA-positive patients often have more classic vasculitic features (like glomerulonephritis), whereas ANCA-negative patients often have more eosinophilic organ infiltration (like heart disease).

8. How often should I see my doctor?
During the active phase, monthly monitoring is common. In remission, quarterly or semi-annual visits are standard.

9. Can I play sports with EGPA?
If the disease is in remission and cardiac function is normal, exercise is encouraged. However, patients with cardiac or significant pulmonary involvement should consult their specialist.

10. What are early warning signs of a relapse?
Increasing asthma symptoms, new skin rashes, sudden numbness/tingling (neuropathy), or unexplained fatigue are common indicators of a flare.

9. Conclusion

EGPA is a rare, complex, and potentially life-threatening disease that requires high clinical suspicion. By identifying the prodromal allergic phase and monitoring for the progression toward vasculitis, clinicians can intervene early to prevent irreversible organ damage. The shift toward targeted biological therapies like Mepolizumab represents a new era in the management of EGPA, offering better outcomes with potentially fewer side effects than traditional cytotoxic chemotherapy.